🔗 Share this article

The first new treatments for gonorrhoea in many years are being viewed as a "major milestone" in the battle against drug-resistant strains of the bacteria, according to scientists.

An International Challenge

Cases of gonorrhoea are increasing globally, with data suggesting more than 82 million infections annually. Notably increased rates are seen in Africa and countries within the World Health Organization's designated area, which spans from China and Mongolia to New Zealand. Across England, cases have reached a record high, while rates across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of new treatments for gonorrhoea is an important and timely development in the reality of rising global incidence, escalating drug resistance and the very limited treatment choices at this time.”

Health officials are deeply concerned about the increase in antibiotic-resistant strains. The World Health Organization has designated it as a "high-priority threat". Ongoing monitoring revealed that resistance to primary antibiotics like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, marketed under the name Nuzolvence, was authorized by the US Food and Drug Administration in December for combating gonorrhoea. This infection can lead to serious health problems, including infertility. Scientists anticipate that targeted use of this new drug will help delay the development of resistance.

Gepotidacin, created by the pharmaceutical company GSK, was also approved in the same week. This treatment, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Approach to Creation

This new treatment was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This milestone represents a major breakthrough in the therapy of multidrug-resistant gonorrhoea, which until now has been evolving faster than medical innovation.”

Testing Results and Global Access

According to data released by a prominent scientific publication, the new drug successfully treated more than 90% of genital gonorrhoea infections. This places it at an comparable level with the current standard treatment, which involves two antibiotics. The trial involved over 900 volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its development partnership, the non-profit has the rights to make available and distribute the drug in many developing nations.

Clinicians treating patients have expressed hope. The availability of a one-pill regimen of this kind is hailed as a "game-changer" for gonorrhoea control. This is viewed as crucial to alleviate the strain of the illness for patients and to prevent the spread of extremely resistant gonorrhoea around the world.